LV Changbing, member of the Party committee and Secretary of the Party committee of Hubei provincial clinical testing center, said in his speech that it is of special significance for Ameson and Roche Diagnostics to hold the signing ceremony during the World Health Expo. Roche Diagnostics is an internationally renowned global diagnostic company with a history of 100 years. Ameson is an innovative R & D enterprise in Wuhan. The collision between the international and the local reflects the importance that Roche Diagnostics attaches to the Chinese market and Wuhan biological enterprises, and also reflects the recognition of Ameson's scientific research and technological strength. This collision is bound to produce dazzling sparks. As a disease with high incidence and serious damage to people's health, the world has devoted a lot of efforts to this. In order to tackle cancer, the National Health Commission launched the 'healthy China 2030' action, and Hubei Province also launched the '323' action. Through its own technology and research and development, Ameson has launched a scheme for early screening and diagnosis of cancer, which is economical, convenient, efficient and sensitive. In line with the needs of the country, the people and the market, we believe that the development prospects of amison are very brilliant and broad.

△ Figure: LV Changbing, member of the Party committee and Secretary of the Party committee of Hubei provincial clinical testing center

Mr. Ni Tao, senior marketing director of Roche Diagnostics, said in his speech that the cooperation between Roche Diagnostics and Ameson is based on the needs of patients. Due to the change of residents' dietary structure, the incidence of digestive tract cancer and colorectal cancer is getting higher and higher. Aiming at the difference between the left and right colon, the sdc2 / TFPI2 double target detection technology pioneered in the world - sdc2 gene methylation is more sensitive to right colon tumors, and TFPI2 gene methylation is more sensitive to left colon tumors, The detection sensitivity of left and right colon cancer can be improved to 95.3%. Combined with Roche's high-precision PCR detection platform, the detection quality will be better guaranteed. Based on the healthy China guidelines, it is recommended that people over 40 years old should be screened for DNA methylation every three years. Based on this, Ameson and Roche diagnosis will expand cooperation in the field of early screening and early diagnosis of tumors in the future, so as to benefit more families and patients. Mr. Chen Jintian, vice president of Roche Diagnostics China, expressed his vision and wishes for the cooperation between the two sides through online means.

△Figure: Mr. Ni Tao, senior marketing director of Roche Diagnostics

Dr. Zhang Lianglu, chairman and general manager of Wuhan amison Life Technology Co., Ltd., said that amison and Roche Diagnostics have good complementary advantages. In the segmented field of early tumor screening, Ameson has the most comprehensive product series in the industry, with both product performance and product convenience. Roche Diagnostics has a product sales and service network all over the country. With its first-class technical products and perfect services, it has won a wide market and reputation. The two sides will continue to deepen the cause of early screening and early diagnosis of tumors, focus on the needs of diagnosis and treatment, and develop more early screening and early diagnosis products with clinical application value. With the use of early screening and early diagnosis products, some cases of early canceration and precancerous lesions have been found in a short period of time, so that some individuals and families can avoid the situation of returning to poverty due to illness and losing money; In the medium and long term, new products will supplement the existing clinical diagnosis path, optimize the allocation of medical resources, and optimize the payment structure of medical insurance through early discovery; In the long run, through the implementation of the universal and convenient cancer screening program, we can truly realize the transformation from passive treatment to active prevention, fundamentally reduce the incidence rate and mortality of cancer, reduce medical costs, and make outstanding contributions to China's medical and health undertakings and the improvement of people's quality of life.

△ Picture: Dr. Zhang Lianglu, chairman of Ameson

In his concluding speech, Chen Honghui, vice mayor of Wuhan, pointed out that the biomedical industry is one of the four national strategic emerging industrial clusters in Wuhan, and is also the key field of Wuhan's great health industry. According to the Wuhan grand health industry plan 2019-2035, Wuhan will build a comprehensive and full cycle grand health industry chain and build a world-class trillion grand health industry cluster. According to the requirements of 'healthy China 2030' and Hubei Province's '323' action plan, we will further promote the early detection, early diagnosis and early treatment of major diseases such as cancer, and reduce the social and economic burden. Hubei Province has taken a series of effective measures to establish the provincial cancer disease prevention and control center, basically forming a three-level network for cancer prevention and control covering the whole province, promoting the monitoring of tumor registration data as a whole, and deeply implementing the three-level prevention of cancer. A key battle for cancer prevention and control is unfolding in the whole province. As a leading enterprise in the field of early screening and early diagnosis of cancer with independent core intellectual property rights technology, Ameson is the fruit of our city's adherence to the line of independent innovation in the field of biomedicine, and is a typical representative of the innovation and development of biomedical enterprises in our city. We hope to give full play to our own advantages and actively participate in the next cancer prevention and treatment work. Roche Diagnostics is a well-known enterprise in the world. It has a complete industrial chain layout and a global market network. It also maintains open cooperation with local medical enterprises in China. It is hoped that the contracted enterprises of both sides can concentrate their efforts to promote the rapid development of the early screening and early diagnosis of cancer, so that more high-quality products and services can benefit the people and go global, and protect the lives and health of more patients.

△ Figure: Chen Honghui, vice mayor of Wuhan

Finally, under the leadership of Vice Mayor Chen Honghui, the signing enterprises and the leaders and guests jointly lit the launching ball of the signing ceremony, and signed the strategic cooperation agreement under the witness of all the leaders and guests on the scene.

△ Figure: signing ceremony